<code id='7CFB359417'></code><style id='7CFB359417'></style>
    • <acronym id='7CFB359417'></acronym>
      <center id='7CFB359417'><center id='7CFB359417'><tfoot id='7CFB359417'></tfoot></center><abbr id='7CFB359417'><dir id='7CFB359417'><tfoot id='7CFB359417'></tfoot><noframes id='7CFB359417'>

    • <optgroup id='7CFB359417'><strike id='7CFB359417'><sup id='7CFB359417'></sup></strike><code id='7CFB359417'></code></optgroup>
        1. <b id='7CFB359417'><label id='7CFB359417'><select id='7CFB359417'><dt id='7CFB359417'><span id='7CFB359417'></span></dt></select></label></b><u id='7CFB359417'></u>
          <i id='7CFB359417'><strike id='7CFB359417'><tt id='7CFB359417'><pre id='7CFB359417'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:75

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In